PEPG

PepGen is a pre-revenue, clinical-stage biotech whose entire value rests on one lead candidate, PGN-EDODM1, in the FREEDOM and FREEDOM2 trials for myotonic dystrophy. The company itself flags in Item 1A that it is 'substantially dependent on the success of our lead product candidate' and has 'no products approved for commercial sale and have not generated any revenue from product sales.' The five-year history confirms this: no revenue in any year (FY2021–FY2025) and net losses that widened from -$27.3M to roughly -$90M annually. Return on equity is -60.8%. This is a pure clinical-outcome lottery ticket, not an operating business you can value on fundamentals.

The balance sheet looks superficially clean — liabilities/equity of just 0.18x and $147M of equity — but that masks the real problem: liquidity versus burn. Cash and equivalents are only $60.5M while operating cash flow was -$81.6M for FY2025. That is under one year of runway at the current burn rate, squarely into the 'Need for Additional Capital' risk the filing leads with. The 'improvement' in the loss metrics (net loss +0.4%, EPS +25.6%) is not operating leverage — the EPS optics come from the share count exploding +111.4% YoY to 69.1M, i.e. heavy dilution has already occurred and, given the cash position, more is almost certainly coming. R&D actually fell 7.1%, which for a company whose only asset is its pipeline is a sign of belt-tightening, not progress.